Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Abstract Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering tr...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	European heart journal Ročník 43; číslo 14; s. 1401 - 1412
Hlavní autori:	Tardif, Jean-Claude, Karwatowska-Prokopczuk, Ewa, Amour, Eric St, Ballantyne, Christie M, Shapiro, Michael D, Moriarty, Patrick M, Baum, Seth J, Hurh, Eunju, Bartlett, Victoria J, Kingsbury, Joyce, Figueroa, Amparo L, Alexander, Veronica J, Tami, Joseph, Witztum, Joseph L, Geary, Richard S, O’Dea, Louis St L, Tsimikas, Sotirios, Gaudet, Daniel
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Oxford University Press 06.04.2022
Predmet:	Apolipoprotein C-III Cardiovascular Diseases - prevention & control Cholesterol Heart Disease Risk Factors Humans Hypertriglyceridemia - complications Hypertriglyceridemia - drug therapy Lipoproteins - therapeutic use Risk Factors Triglycerides Cardiovascular disease Antisense apoC-III Cardiovascular risk factors Hypertriglyceridaemia Atherosclerosis
ISSN:	0195-668X, 1522-9645, 1522-9645
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!